Garth LeesRolfe - Inhibikase Therapeutics Chief Officer

Inhibikase Therapeutics Management Efficiency

The company has Return on Asset of (0.7621) % which means that on every $100 spent on assets, it lost $0.7621. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.4969) %, meaning that it generated no profit with money invested by stockholders. Inhibikase Therapeutics' management efficiency ratios could be used to measure how well Inhibikase Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.38 in 2024. Return On Capital Employed is likely to gain to -1.72 in 2024. At this time, Inhibikase Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 18.3 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 85.6 K in 2024.

Similar Executives

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinsons Disease and related disorders that arise inside and outside of the brain. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia. Inhibikase Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people. Inhibikase Therapeutics (IKT) is traded on NASDAQ Exchange in USA. It is located in 3350 Riverwood Parkway SE, Atlanta, GA, United States, 30339 and employs 8 people. Inhibikase Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Inhibikase Therapeutics Leadership Team

Inhibikase Stock Performance Indicators

Additional Tools for Inhibikase Stock Analysis